Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italia.
Medical Oncology Unit, "Mons. R. Dimiccoli" Hospital, Barletta (BT), ASL BT, Barletta, Italy.
Expert Opin Investig Drugs. 2022 Jun;31(6):557-565. doi: 10.1080/13543784.2022.2009456. Epub 2021 Dec 13.
Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports the exploration of strategies for increasing the efficacy of immunotherapy. To enhance overall response and clinical outcomes, several immune-based combinations are being investigated.
The authors present a synopsis of current, state-of-art immune-based combinations in this setting and reflect on future possibilities. They shed light on recently presented and published clinical trials and ongoing studies. A literature search was conducted in October 2021; in addition, abstracts of international cancer meetings were reviewed.
Clinical trials suggest that ICI monotherapy could be beneficial in a minority of mTNBC patients; conversely, several immune-based combinations have reported notable results in recently presented or published studies. Some of these combination strategies have been approved for mTNBC - as in the case of chemoimmunotherapy in PD-L1 positive patients. Numerous trials are investigating novel ICI-based combinations and their results are eagerly awaited.
免疫检查点抑制剂 (ICI) 单药治疗似乎对一小部分转移性三阴性乳腺癌 (mTNBC) 患者有效。这支持了探索提高免疫疗法疗效的策略。为了提高整体反应和临床结果，正在研究几种基于免疫的联合治疗。
作者在该背景下总结了当前最先进的基于免疫的联合治疗方法，并对未来的可能性进行了思考。他们介绍了最近提出和发表的临床试验和正在进行的研究。文献检索于 2021 年 10 月进行；此外，还回顾了国际癌症会议的摘要。
临床试验表明，ICI 单药治疗可能对少数 mTNBC 患者有益；相反，一些基于免疫的联合治疗在最近提出或发表的研究中报告了显著的结果。其中一些联合治疗策略已被批准用于 mTNBC，例如 PD-L1 阳性患者的化疗免疫治疗。许多试验正在研究新型基于 ICI 的联合治疗方法，人们热切期待着它们的结果。
